Literature DB >> 16126400

Type of resection and prognosis in lung cancer. Experience of a multicentre study.

Ramón Rami-Porta1, Miquel Mateu-Navarro, Jordi Freixinet, Mercedes de la Torre, Antonio José Torres-García, Yat-Wah Pun, Antonio Cantó Armengod.   

Abstract

OBJECTIVE: Analysis of prognosis of the different types of resections for lung cancer defined by the Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S).
METHODS: From October 1993 to September 1997, 2994 patients with bronchogenic carcinoma who underwent thoracotomy were prospectively recruited by the GCCB-S. Prior to recruitment, the GCCB-S had defined two types of non-resectional operations (diagnostic and exploratory thoracotomies) and three types of resections (complete-CR-: free resection margins, mediastinal nodal dissection, no extracapsular nodal involvement, no involvement of most distant removed nodes; relatively incomplete-RIR-: free resection margins, no mediastinal nodal dissection, unremoved nodes, involvement of most distant removed nodes, positive pleural effusion with no pleural implants; and incomplete-IR-: positive resection margins, extracapsular nodal involvement, unremoved positive nodes, positive pleural effusion with pleural implants). For survival analyses, patients with small cell carcinoma, induction therapy, postoperative mortality, unclassified operation, or lost to follow-up were excluded. The total number of evaluable patients was 2543.
RESULTS: In 1047 (97%) patients, RIR was defined because they had undergone a lesser nodal evaluation than mediastinal nodal dissection. Five-year survival and 95% confidence interval were: diagnostic thoracotomy 11% (0-30%), exploratory thoracotomy 5% (1-9%), IR 20% (14-26%), RIR 43% (39-47%), and CR 45% (41-49%). Differences between IR and CR or RIR were statistically significant (P<0.0001), but those between CR and RIR were not (P=0.18).
CONCLUSIONS: CR and RIR should be combined in a single category as complete resection, because they do not discriminate prognostic differences.

Entities:  

Mesh:

Year:  2005        PMID: 16126400     DOI: 10.1016/j.ejcts.2005.06.026

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Unexpected extensions of non-small-cell lung cancer diagnosed during surgery: revisiting exploratory thoracotomies and incomplete resections.

Authors:  Christophe Foucault; Pierre Mordant; Bertrand Grand; Karima Achour; Alex Arame; Antoine Dujon; Françoise Le Pimpec Barthes; Marc Riquet
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-01-23

2.  Relationship of immunohistochemical biomarker expression and lymph node involvement in patients undergoing surgical treatment of NSCLC with long-term follow-up.

Authors:  Ana María Gómez; Jose Ramón Jarabo Sarceda; Jose Antonio L García-Asenjo; Cristina Fernandez; Susana Hernandez; Julian Sanz; Elena Fernandez; Joaquin Calatayud; Antonio Torres; Florentino Hernando
Journal:  Tumour Biol       Date:  2014-01-19

3.  Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients.

Authors:  Andrea Bille; Kaitlin M Woo; Usman Ahmad; Nabil P Rizk; David R Jones
Journal:  Eur J Cardiothorac Surg       Date:  2017-04-01       Impact factor: 4.191

Review 4.  Is there a survival advantage of incomplete resection of non-small-cell lung cancer that is found to be unresectable at thoracotomy?

Authors:  Keltie Dall; Christopher Ford; Rachael Fisher; Joel Dunning
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-01-11

5.  Oncological outcomes of unsuspected pN2 in patients with non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Michiel A IJsseldijk; Richard P G Ten Broek; Bastiaan Wiering; Edo Hekma; Marnix A J de Roos
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-10

6.  Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer.

Authors:  Magda Palka; Antonio Sanchez; Mar Córdoba; Gema Díaz Nuevo; Andrés Varela De Ugarte; Blanca Cantos; Miriam Méndez; Virginia Calvo; Constanza Maximiano; Mariano Provencio
Journal:  Oncol Lett       Date:  2017-01-18       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.